Started: 5/2017
Study Name: An Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with XXX(0.025%) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis”
Indication: Psoriasis
Principal Investigator: Sahra Niazi